Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.55 -2.3%	$2.18	$0.80 ▼ $3.42	$104.75M	-0.88	166,472 shs	16,248 shs
BMEA Biomea Fusion	$1.92 +3.2%	$1.77	$1.29 ▼ $13.07	$114.26M	-0.14	1.34 million shs	1.58 million shs
MGNX MacroGenics	$1.70 -1.2%	$1.52	$0.99 ▼ $5.10	$107.46M	1.65	909,067 shs	659,122 shs
MIRA MIRA Pharmaceuticals	$1.40 +2.2%	$1.45	$0.73 ▼ $2.56	$26.70M	1.77	1.06 million shs	84,953 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	-6.28%	+3.57%	-16.88%	+154.63%	+28.57%
BMEA Biomea Fusion	+1.64%	+4.49%	+3.33%	+24.83%	-76.28%
MGNX MacroGenics	-4.97%	+15.44%	+2.99%	+22.86%	-49.85%
MIRA MIRA Pharmaceuticals	-1.44%	-3.52%	-20.35%	+2.24%	-30.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.3507 of 5 stars	3.3	3.0	0.0	3.3	1.7	0.0
BMEA Biomea Fusion	3.6954 of 5 stars	4.6	3.0	0.0	2.2	2.5	0.6
MGNX MacroGenics	4.3894 of 5 stars	3.3	3.0	4.4	2.8	4.2	0.0
MIRA MIRA Pharmaceuticals	3.0019 of 5 stars	3.8	5.0	0.0	2.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	114.84% Upside
BMEA Biomea Fusion	3.15	Buy	$15.73	700.37% Upside
MGNX MacroGenics	2.57	Moderate Buy	$3.60	103.74% Upside
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,119.51% Upside

Current Analyst Ratings Breakdown

Latest MIRA, BMEA, ANEB, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	BMEA Biomea Fusion	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
MGNX MacroGenics	$149.96M	0.74	N/A	N/A	$0.74 per share	2.39
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.57	N/A	N/A	N/A	-21.99%	-40.24%	-14.62%	11/4/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-406.70%	-328.44%	11/11/2025 (Estimated)

Latest MIRA, BMEA, ANEB, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/24/2025	Q4 2025	ANEB Anebulo Pharmaceuticals	-$0.05	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
BMEA Biomea Fusion	N/A	3.68	3.68
MGNX MacroGenics	N/A	5.26	5.02
MIRA MIRA Pharmaceuticals	N/A	2.80	2.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BMEA Biomea Fusion	96.72%
MGNX MacroGenics	96.89%
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BMEA Biomea Fusion	18.42%
MGNX MacroGenics	13.00%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
MGNX MacroGenics	430	63.21 million	54.99 million	Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable

MIRA, BMEA, ANEB, and MGNX Headlines

Recent News About These Companies

MIRA Pharmaceuticals (NASDAQ:MIRA) Upgraded at Wall Street Zen

August 25 at 2:19 AM | americanbankingnews.com

Mira Pharmaceuticals completes Phase 1 SAD portion for oral Ketamir-2

August 20, 2025 | msn.com

MIRA Pharmaceuticals Completes Phase 1 Trial for Ketamir-2

August 19, 2025 | tipranks.com

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

August 19, 2025 | accessnewswire.comA

MIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus ...

August 14, 2025 | dispatch.com

MIRA Pharmaceuticals’ Ketamir-2 Shows Promising Preclinical Results

August 12, 2025 | msn.com

Mira announces acceptance of second Ketamir-2 manuscript for publication

August 12, 2025 | msn.com

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine ...

August 12, 2025 | finance.yahoo.com

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

August 12, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Announces Virtual Annual Meeting to Discuss SKNY Merger

August 9, 2025 | msn.com

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

July 30, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

July 29, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Gets FDA Clearance for Ketamir-2 Trials

July 28, 2025 | tipranks.com

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for ...

July 11, 2025 | sacbee.comS

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

July 11, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Reports Promising SKNY-1 Preclinical Results

July 10, 2025 | tipranks.com

Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 10, 2025 | uk.finance.yahoo.com

Mira Pharmaceuticals raises $2 million through at-the-market stock sale

July 9, 2025 | investing.com

MIRA Pharmaceuticals Raises $2M Through Stock Sale

July 8, 2025 | tipranks.com

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

July 3, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIRA, BMEA, ANEB, and MGNX Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.55 -0.06 (-2.30%)

Closing price 03:57 PM Eastern

Extended Trading

$2.52 -0.02 (-0.98%)

As of 04:10 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Biomea Fusion NASDAQ:BMEA

$1.92 +0.06 (+3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 0.00 (0.00%)

As of 05:40 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

MacroGenics NASDAQ:MGNX

$1.70 -0.02 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.03 (+1.47%)

As of 05:42 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.40 +0.03 (+2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 +0.03 (+1.79%)

As of 05:20 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time